|Bid||4.63 x 1200|
|Ask||12.00 x 800|
|Day's Range||7.14 - 7.68|
|52 Week Range||3.57 - 19.84|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||4.31|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.67|
Subscribe to Yahoo Finance Plus to view Fair Value for LYEL
The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 93.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shareholders in Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) may be thrilled to learn that the analysts have just delivered...
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?